Analysis of Circulating Apoptosis Mediators and Proinflammatory Cytokines in Patients With Idiopathic Hypertrophic Cardiomyopathy Comparison Between Nonobstructive and Dilated-Phase Hypertrophic Cardiomyopathy
Open Access
- 1 January 2005
- journal article
- research article
- Published by International Heart Journal (Japanese Heart Journal) in International Heart Journal
- Vol. 46 (2), 231-244
- https://doi.org/10.1536/ihj.46.231
Abstract
We examined the plasma levels of soluble Fas (sFas) or Fas ligand (sFas-L), tumor necrosis factor-alpha (TNF-α), and interleukin-6 (IL-6) in patients with idiopathic nonobstructive (HNCM) and dilated-phase (DHCM) hypertrophic cardiomyopathy. Patients with idiopathic hypertrophic cardiomyopathy (HCM) may deteriorate to DHCM and the pathogenesis is unknown. The levels of these plasma cytokines were measured by ELISA and echocardiography was performed in 38 HNCM and 11 DHCM patients, and 10 normal subjects. The follow-up period was three years. In HNCM, TNF-α (43.3 ± 45.2 versus 16.9 ± 4.3 pg/mL) and IL-6 (65.1 ± 86.4 versus 4.0 ± 2.1 pg/mL) were slightly higher compared to normal subjects and sFas (3.7 ± 1.2 versus 2.1 ± 0.7 ng/mL) increased significantly. sFas (3.9 ± 1.8), TNF-α (79.3 ± 72.4), and IL-6 (234.1 ± 135.2) in DHCM were significantly increased and only IL-6 was significantly different from HNCM. sFas-L (0.18 ± 0.08 versus 0.25 ± 0.05 ng/mL) in HNCM was significantly decreased, and the decrease was marked in DHCM (0.05 ± 0.02). In HNCM, TNF-α was negatively correlated with fractional shortening (r = -0.432, P = 0.0062) or positively with IL-6 (r = 0.665, P < 0.0001), while sFas-L was negatively correlated with IL-6 (r = -0.580, P < 0.0001). DHCM with high sFas had significantly higher cumulative incidences of worsening heart failure. The Fas/Fas-L system and proinflammatory cytokines may play an important role in the status of HCM and its progression to DHCM.Keywords
This publication has 37 references indexed in Scilit:
- Decreased circulating Fas ligand in patients with familial combined hyperlipidemia or carotid atherosclerosis: Normalization by atorvastatinJournal of the American College of Cardiology, 2004
- Elevated circulating levels and cardiac secretion of soluble fas ligand in patients with congestive heart failureThe American Journal of Cardiology, 1999
- Levels of Soluble Fas in Patients With Myocarditis, Heart Failure of Unknown Origin, and in Healthy VolunteersThe American Journal of Cardiology, 1998
- Fas and Fas ligand in embryos and adult mice: ligand expression in several immune-privileged tissues and coexpression in adult tissues characterized by apoptotic cell turnover.The Journal of cell biology, 1996
- Increased circulating cytokines in patients with myocarditis and cardiomyopathy.Heart, 1994
- Protection from Fas-Mediated Apoptosis by a Soluble Form of the Fas MoleculeScience, 1994
- Molecular cloning and expression of the fas ligand, a novel member of the tumor necrosis factor familyCell, 1993
- Hypertrophic cardiomyopathyCurrent Problems in Cardiology, 1993
- Occurrence and significance of progressive left ventricular wall thinning and relative cavity dilatation in hypertrophic cardiomyopathyThe American Journal of Cardiology, 1987
- Thallium perfusion and cardiac enzyme abnormalities in patients with familial hypertrophic cardiomyopathyAmerican Heart Journal, 1985